
BioPharm International Sponsored eBooks-09-15-2021
Biopharmaceutical companies are tasked with doing more with less while moving promising biotherapeutics into the clinic as fast as safely possible. Advances in High-Throughput Upstream Process Development takes a deep dive into an approach that addresses this challenge: combining definitive screening designs with advanced machine learning for accelerated drug development. Explore:
- Phase appropriate DOE strategies to minimize development timelines and maximize product life-cycle efficiency
- Efficient sample transfer from bioreactor to analytical platform
- Organizational strategies for data management from research to GMP production

Advertisement
Advertisement
Trending on BioPharm International
1
FDA Rejects Summit’s PD-1×VEGF Bispecific Ivonescimab in EGFR-Mutated NSCLC, Citing Lack of Survival Benefit
2
FDA Approves Cosentyx as First Anti-IL-17 Biologic for Polymyalgia Rheumatica
3
Deals Roundup: J&J Buys Ollin, Lilly Adds Calytrix, and Novartis and Sanofi Strike Platform Pacts
4
One Injection a Month: Efimosfermin Takes Aim at Cirrhosis in MASH
5
